Literature DB >> 12670909

Genetic determinants of malignancy in a mouse model for oligodendroglioma.

William A Weiss1, Michael J Burns, Christopher Hackett, Ken Aldape, John R Hill, Hiroko Kuriyama, Nagato Kuriyama, Nadezhda Milshteyn, Tim Roberts, Michael F Wendland, Ron DePinho, Mark A Israel.   

Abstract

Oligodendrogliomas of all grades overexpress epidermal growth factor receptor (EGFR), whereas deletion of ink4a/arf is found only in high-grade tumors. We used the S100 beta promoter to generate transgenic mice expressing v-erbB, a transforming allele of EGFR. These mice developed low-grade oligodendroglioma. Transgenic animals heterozygous for ink4a/arf or p53 developed high-grade tumors. Comparative genomic hybridization revealed loss of distal mouse chromosome 4, a region orthologous with human chromosome 1p, which is commonly lost in oligodendroglioma. Our results demonstrate that overexpression of EGFR, an epigenetic observation of uncertain significance in human oligodendroglioma, can initiate oligodendroglioma in the mouse. Furthermore, p53 pathway mutations can mediate the transition from low to high grade. These models hold promise for studying tumor lineage, identifying contributing genetic alterations and evaluating preclinical therapies in this important neoplasm.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670909

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Authors:  Youngmi Kim; Eunhee Kim; Qiulian Wu; Olga Guryanova; Masahiro Hitomi; Justin D Lathia; David Serwanski; Andrew E Sloan; Robert J Weil; Jeongwu Lee; Akiko Nishiyama; Shideng Bao; Anita B Hjelmeland; Jeremy N Rich
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 3.  The mammalian ovary from genesis to revelation.

Authors:  Mark A Edson; Ankur K Nagaraja; Martin M Matzuk
Journal:  Endocr Rev       Date:  2009-09-23       Impact factor: 19.871

Review 4.  Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

Authors:  Tiffany T Huang; Shawn M Sarkaria; Timothy F Cloughesy; Paul S Mischel
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

5.  Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk.

Authors:  Karlyne M Reilly
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

6.  Cancer stem cells are enriched in the side population cells in a mouse model of glioma.

Authors:  Molly A Harris; Hyuna Yang; Benjamin E Low; Joydeep Mukherjee; Joydeep Mukherje; Abhijit Guha; Roderick T Bronson; Leonard D Shultz; Mark A Israel; Kyuson Yun
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 7.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

8.  STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma.

Authors:  Jasmine Lau; Shirin Ilkhanizadeh; Susan Wang; Yekaterina A Miroshnikova; Nicolas A Salvatierra; Robyn A Wong; Christin Schmidt; Valerie M Weaver; William A Weiss; Anders I Persson
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

Review 9.  Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.

Authors:  Leon Chen; Yuqing Zhang; Jingxuan Yang; John P Hagan; Min Li
Journal:  Biochim Biophys Acta       Date:  2013-04-22

Review 10.  Genetically engineered mouse models of brain cancer and the promise of preclinical testing.

Authors:  Jason T Huse; Eric C Holland
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.